Patients should be informed of the possibility of hypersensitivity reactions, including immediate anaphy-laxis, to ONCASPAR^Ò . Patients taking ONCASPAR^Ò are at higher than usual risk for bleeding problems. Patients should be instructed that the simultaneous use of ONCASPAR^Ò with other drugs that may increase the risk of bleeding should be avoided (SEE DRUG INTERACTIONS). ONCASPAR^Ò may affect the ability of the liver to function normally in some patients. Therapy with ONCASPAR^Ò may increase the toxicity of other medications (SEE DRUG INTERACTIONS). ONCASPAR^Ò may have immunosuppressive activity. Therefore, it is possible that use of the drug in patients may predispose the patient to infection. Patients should notify their physicians of any adverse reactions that occur.

Bookmark this page: